The prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read moreThe prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read more
MASH CRO Expertise for Complex Clinical Trials As MASH clinical development continues to evolve, sponsors face increasing challenges in patient identification, complex eligibility criteria, high screening failure rates, and competition for experi...
How a Site-Centric Delivery Model Accelerated Study Start-Up When a Phase II Parkinson’s disease study faced aggressive start-up and enrollment targets, the study team was tasked with achieving first patient consent within just eight weeks of f...
Comparing FIB-4 and MAF-5 for Advanced Fibrosis Screening in Primary Care Complete the form to access the poster and explore the preliminary GRIPonMASH findings.[gravityform id="19" title="false"]As the prevalence of MASLD and MASH contin...
"*" indicates required fields
"*" indicates required fields
